Proteon Therapeutics, Inc. (PRTO)

[Titan V]

SA article from Bret Jensen:

Next up is microcap Proteon Therapeutics (PRTO). It is being maintained as a Buy with a $5 price target over at Maxim Group this morning with the following commentary.

PRTO shares have traded up over 20% since 3/1/19. We believe this may be in anticipation of the P3 PATENCY-2 data, which is expected this month. As a reminder, PATENCY-2 was amended based on the results of PATENCY-1, which we see as de-risking. A combination of prior data, FDA feedback, the current trial’s design and the unmet need in the space lead us to see a favorable risk/reward profile.

https://seekingalpha.com/instablog/498952-bret-jensen/5278922-4-notable-analyst-calls